Meeting
2023 ASCO Gastrointestinal Cancers Symposium
Achievement of cancer- and treatment-free status by atezolizumab plus bevacizumab combined with or without curative conversion in patients with transarterial chemoembolization-unsuitable, intermediate-stage hepatocellular carcinoma: A multicenter cohort study.
Authors
Masatoshi Kudo
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan;
Masatoshi Kudo , Tomoko Aoki , Kazuomi Ueshima , Kaoru Tsuchiya , Masahiro Morita , Satoru Hagiwara , Yasunori Minami , Hiroshi Ida , Naoshi Nishida , CHIKARA OGAWA , Tetsu Tomonari , Noriaki Nakamura , Hidekatsu Kuroda , Atsushi Takebe , Yoshifumi Takeyama , Masaaki Hidaka , Susumu Eguchi , Stephen Lam Chan , Masayuki Kurosaki , Namiki Izumi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03434379
Citation
J Clin Oncol 41, 2023 (suppl 4; abstr 535)
DOI
10.1200/JCO.2023.41.4_suppl.535
Abstract #
535
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima
Poster
2021 ASCO Annual Meeting
The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.
First Author: David Trueman
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Fruquintinib combined with sintilimab plus transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma: A single-arm phase II study.
First Author: Guoliang Shao
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Second-line regorafenib in patients (pts) with unresectable hepatocellular carcinoma (uHCC) after progression on first-line atezolizumab plus bevacizumab (Atezo-Bev): Phase 2 REGONEXT trial.
First Author: Changhoon Yoo